menu
    • menu
    [{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Meitheal Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Meitheal Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Valeo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Valeo Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valeo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Valeo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Meitheal Pharmaceuticals","sponsor":"Premier","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"Antithrombin III","graph1":"Hematology","graph2":"Undisclosed","graph3":"Meitheal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"Meitheal Pharmaceuticals \/ Premier Inc","highestDevelopmentStatusID":"1","companyTruncated":"Meitheal Pharmaceuticals \/ Premier Inc"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Techdow USA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Techdow USA \/ Not Applicable"},{"orgOrder":0,"company":"Techdow USA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Techdow USA","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Pre-Filled Syringe","sponsorNew":"Techdow USA \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Techdow USA \/ Not Applicable"},{"orgOrder":0,"company":"Minapharm Pharmaceuticals","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"EGYPT","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Enoxaparin Sodium","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Minapharm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Minapharm Pharmaceuticals \/ Sanofi","highestDevelopmentStatusID":"12","companyTruncated":"Minapharm Pharmaceuticals \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enoxaparin Sodium","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sanofi \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Enoxaparin Sodium

    Menu

    Enoxaparin Sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sanofi

                            France
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sanofi Delivers First Medicines from Global Health Unit’s Impact Brand Portfolio

                            Details : Lovenox (enoxaparin sodium) is a novel small molecule Antithrombin-III activator. It is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis.

                            Brand Name : Lovenox

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 19, 2023

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Minapharm Pharmaceuticals

                            Egypt arrow
                            Antibody Engineering
                            Not Confirmed

                            Minapharm Pharmaceuticals

                            Egypt arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the Manufacture of Clexane®

                            Details : The agreement aims for the for the localization of the full range of its flagship market leader product, Clexane (enoxaparin sodium), used to prevent clots from getting bigger or stopping new clots from forming.

                            Brand Name : Clexane

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 10, 2023

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Techdow USA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Techdow USA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Techdow USA Announces Launch of its Generic Lovenox, (Enoxaparin Sodium – Preservative Free) in Prefilled Sy...

                            Details : Lovenox-Generic (enoxaparin sodium) is a Factor XI/XIa inhibitor with a Prefilled Syringes with 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths low molecular weight heparin (LMWH), is an anticoagulant that helps to prevent thrombosis.

                            Brand Name : Lovenox-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 08, 2023

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Techdow USA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Techdow USA

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Techdow USA Announces FDA Approval of Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) In Prefille...

                            Details : Enoxaparin sodium binds to antithrombin III, a serine protease inhibitor, forming a complex that irreversibly inactivates factor Xa, which is frequently used to monitor anticoagulation in the clinical setting.

                            Brand Name : Lovenox-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 20, 2023

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Premier

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Meitheal Pharmaceuticals Announces Findings from Collaborative Research Study with Premier Inc. Evaluating Ant...

                            Details : Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes in Covid-19 patient.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2021

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Premier

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Valeo Pharma

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed

                            Valeo Pharma

                            Canada arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Valeo Pharma’s Redesca™ Receives Positive Recommendation for Public Reimbursement in Quebec

                            Details : Redesca™ is a low molecular weight heparin biosimilar. LMWHs are injectable anticoagulant drugs used primarily to treat and prevent deep vein thrombosis and pulmonary embolism.

                            Brand Name : Redesca

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 25, 2021

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Meitheal Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Meitheal Pharmaceuticals Announces Launch of Enoxaparin Sodium Injection, USP in the United States

                            Details : Meitheal Pharmaceuticals has launched Enoxaparin Sodium Injection, generic equivalent of Lovenox®, in the United States market. Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharma...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 28, 2020

                            Lead Product(s) : Enoxaparin Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth